FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(France or 1)	pe response	,5)															
Name and Address of Reporting Person * Cheong Kwang Soo				2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
(Last) (First) (Middle) C/O REXAHN PHARMACEUTICALS,				3. Date of Earliest Transaction (Month/Day/Year) 06/18/2012							X Director 10% Owner Officer (give title below) Other (specify below)						
INC., 15245 SHADY GROVE ROAD, SUITE 455 (Street)				4. If Amendment, Date Original Filed(Month/Day/Year) 6								6. Indivi	dual o	r Joint/Grou	up Filing(Chec	k Applicable Lin	e)
ROCKVI	ILLE, MD	20850						<i>5</i>				_X_ Form	filed by	One Reporting			
(Cit		(State)	(Zip)			Tal	ble I	- Non-Deri	ivati	ve Securities	Acqui	ired, Dis	posed	of, or Bene	eficially Owi	ied	
1.Title of S	Security		2. Transaction	2A. De		d í	3. Tra	ansaction		ecurities Acq				Securities B	eneficially	6. 7	. Nature
(Date (Month/Day/Year	Execution Date, if any (Month/Day/Year			Code (Instr			or Disposed of tr. 3, 4 and 5)		f (D) Owned Follow Transaction(s) (Instr. 3 and 4))			f Indirect eneficial wnership
				(Wionin	/Da	y/ i cai)				(A) or		(IIISII. 3	anu +,			or Indirect (I)	
						Со	ode V	Am	ount (D)	Price					(Instr. 4)		
Common Stock											3,000				D		
Reminder:	Report on a	separate line for eac	h class of securities	benefici	ally	owned d	irectl		-								
								contai	inec	who respon d in this for:	m are	not requ	uired	to respon	d unless th		174 (9-02)
								form o	disp	lays a curre	ently v	alid ON	ИВ со	ntrol num	ber.		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of		3. Transaction	3A. Deemed	4.		5. Num		6. Date Ex	kerci	sable and	7. Titl	le and			9. Number o		11. Nature
Security	Conversion or Exercise		Execution Date, if any	Code		Derivat		Secur			erlying Security			Securities	Ownershi Form of	Beneficial	
(Instr. 3)	Price of Derivative		(Month/Day/Year)	(Instr. 8)	Securiti Acquire									Beneficially Owned	Derivative Security:	Ownership (Instr. 4)
	Security			(A) or Disposed of							Following Reported	Direct (D) or Indirec					
				(D) (Instr. 3, 4,							Transaction (Instr. 4)	(s) (I) (Instr. 4)					
						and 5)	, .,								(======================================	(
								Date		Expiration		or					
								Exercisab	le	Date	Title	Nu of	ımber				
Stock				Code	V	(A)	(D)					Sh	ares				
Options	\$ 0.38	06/18/2012		A		20,000		<u>(1)</u>		06/18/2022	Com	mon 20	0,000	\$ 0	20,000	D	
(right- to-buy)	\$ 0.56	00/10/2012		Λ		20,000				00/10/2022	Sto	ock 20	,,000	\$0	20,000		
Stock																	
Options	\$ 1.25							06/06/20)12	06/06/2021	Com	120	0,000		20,000	D	
(right- to-buy)	,										Sto	ock	,		,,,,,,,		
Stock																	
Options	\$ 1.17							06/14/20)11	06/14/2020	Com Sto		,000		20,000	D	
(right- to-buy)											Sio	OCK					
Stock																	
Options (right-	\$ 1.28							06/01/20	010	06/01/2019	Com Sto	170	,000		20,000	D	
to-buy)																	
Stock Options											Com	mon					
(right-	\$ 3.24							06/30/20	009	06/30/2018	Sto	170	,000		20,000	D	
to-buy)																	
Stock Options	0.1.10							06/11/120	100	06/11/2017	Com	mon 20			20.000		
(right-	\$ 1.40							06/11/20	908	06/11/2017	Sto	ock 20	,000		20,000	D	
to-buy) Stock																	
Options	\$ 1.20							05/01/20	007	05/01/2016	Com	mon 20	000		20,000	D	
(right- to-buy)	Ψ 1.20							33/31/20	,	05/01/2010	Sto	ock 20	,,,,,,		20,000		

Reporting Owners

Daniel Comment Name / Address	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Cheong Kwang Soo C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850	X							

Signatures

/s/ Tae Heum Jeong, as attorney-in-fact for Kwang Soo Cheong	06/20/2012	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, \emph{see} Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These options vest and become exercisable in full on June 18, 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.